Search companies

Live

NEURIZON THERAPEUTICS LIMITED (ASX: NUZ)

Health care · News and insights

Price unavailable

Latest NUZ announcements

Announcement Insights

Neurizon Raises Capital Ahead Of Earlier ALS Trial Readout

Neurizon has completed enrolment in its 250-person HEALEY ALS trial, bringing expected topline results forward to late Q2 2027, while assembling funding intended to carry it through the readout. After reporting A$11 million in cash in October, it secured A$4.3 million through a placement, redeemed all remaining convertible notes and opened a shareholder plan targeting A$2 million, with the option to accept up to A$10 million; the plan is not underwritten and may be scaled back. The company also extended its R&D financing facility through FY2027 and had drawn approximately A$12 million in total before related tax rebates.

Updated 16 Nov 2026, 09:49 AM Sydney time
Share
SourcesShare Purchase Plan and Options Offer OpenProspectusNotice of General Meeting/Proxy FormUpdate - Proposed issue of securities - NUZUpdate - Proposed issue of securities - NUZR&D Facility Extension and Second Drawdown CompletedFirst Regimen I patient enters Active Treatment ExtensionChange in substantial holdingApplication for quotation of securities - NUZApplication for quotation of securities - NUZSection 708A Cleansing StatementApplication for quotation of securities - NUZInvestor webinar reminder and presentationFirm commitments to raise A$4.3m and announcement of SPPProposed issue of securities - NUZProposed issue of securities - NUZRedemption of all remaining Obsidian convertible notesWithdrawal of Resolution 4 from Notice of AGMNotification of cessation of securities - NUZTrading HaltAppendix 4C & Quarterly Update
Comments

Neurizon Opens Share Plan, Allows SPP to Raise Up to $10 Million

2026-11-16 · Health care

NUZ: $0.059 +1.72% · MC: $48M

Neurizon has opened its share purchase plan, targeting $2 million at the same price as its recent placement, while reserving the right to accept oversubscriptions up to $10 million; the offer is not underwritten and may be scaled back. Eligible shareholders may also be offered one option for each share subscribed for, subject to shareholder approval and ASX quotation requirements. Proceeds are intended to support clinical work, including the HEALEY ALS trial, whose topline results are anticipated in late Q2 CY2027.

Updated 2026-11-16 09:43
Share
SourcesShare Purchase Plan and Options Offer OpenProspectusNotice of General Meeting/Proxy FormUpdate - Proposed issue of securities - NUZUpdate - Proposed issue of securities - NUZ
Comments

Neurizon Extends R&D Facility, Draws $12 Million Ahead Of ALS Trial Results

2026-11-13 · Health care

NUZ: $0.058 +1.75% · MC: $48M

Neurizon Therapeutics has extended its non-dilutive R&D financing facility to cover FY2027 and drawn approximately $3.7 million, bringing total advances to approximately $12 million before receiving the related tax rebates. Separately, the first participant in its HEALEY ALS trial’s Regimen I has entered the treatment extension after completing the randomised phase; topline results remain anticipated in late Q2 2027.

Updated 2026-11-13 09:45
Share
SourcesR&D Facility Extension and Second Drawdown CompletedFirst Regimen I patient enters Active Treatment Extension
Comments

Neurizon Issues Over 63 Million Shares, Including Placement Shares and Vested Rights

2026-11-09 · Health care

NUZ: $0.060 -6.25% · MC: $48M

Neurizon Therapeutics issued over 63 million ordinary shares, including shares from its previously announced placement, vested performance rights and part-payment for investor relations services. The placement accounts for most of the issue; the performance-right conversion also reduced the remaining rights on issue.

Updated 2026-11-09 09:38
Share
SourcesApplication for quotation of securities - NUZApplication for quotation of securities - NUZSection 708A Cleansing Statement
Comments

Neurizon Moves Ahead With $4.3 Million Share Placement

2026-11-06 · Health care

NUZ: $0.064 +3.23% · MC: $48M

Neurizon Therapeutics has applied to quote shares from its previously announced placement, with the new shares due to be issued next week. The placement forms part of a funding package intended to replace a potential drawdown under its convertible-note facility; shares for participating directors and the Share Purchase Plan are still to be issued, with director shares subject to shareholder approval.

Updated 2026-11-06 10:58
Share
SourcesApplication for quotation of securities - NUZ
Comments

Neurizon Sets Out Funding Plan Ahead Of ALS Trial Results

2026-11-05 · Health care

NUZ: $0.062 -4.62% · MC: $48M

Neurizon’s investor presentation recaps its $4.3 million placement and proposed $2 million share purchase plan, alongside redemption of all remaining Obsidian convertible notes. The company says the funding is intended to strengthen its position ahead of anticipated HEALEY ALS Platform Trial results in late Q2 2027; the webinar is scheduled for today.

Updated 2026-11-05 10:05
Share
SourcesInvestor webinar reminder and presentation
Comments

Neurizon Raises A$4.3 Million, Targets Further A$2 Million as It Clears Convertible Notes

2026-11-02 · Health care

NUZ: $0.065 -24.42% · MC: $48M

Neurizon Therapeutics has secured firm commitments for a A$4.3 million share placement and is targeting a further A$2 million through a shareholder plan, replacing a potential drawdown under its convertible-note facility. It has redeemed all remaining notes, leaving none on issue and removing potential conversion dilution; the company says it remains funded through the HEALEY trial’s expected topline readout. The new funding follows its October quarterly update, which reported A$11 million in cash and said it was fully funded through the readout.

Updated 2026-11-02 10:01
Share
SourcesProposed issue of securities - NUZFirm commitments to raise A$4.3m and announcement of SPPProposed issue of securities - NUZRedemption of all remaining Obsidian convertible notesNotification of cessation of securities - NUZWithdrawal of Resolution 4 from Notice of AGM
Comments

Neurizon completes enrolment in ALS trial, bringing topline results forward

2026-10-28 · Health care

NUZ: $0.086 +0.00% · MC: $48M

Neurizon Therapeutics completed enrolment of 250 participants in the HEALEY ALS trial, bringing the anticipated topline readout forward to late Q2 2027. The FDA said the trial could potentially serve as the single study supporting a traditional approval application, subject to results meeting effectiveness requirements; an NIH grant will fund an expanded-access program for up to 200 people with ALS. Neurizon reported cash of $11 million at quarter-end and said it remains funded through the trial readout.

Updated 2026-10-28 09:40
Share
SourcesAppendix 4C & Quarterly Update
Comments